PMID- 36399686
OWN - NLM
STAT- MEDLINE
DCOM- 20230116
LR  - 20230210
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 21
IP  - 1
DP  - 2023 Jan
TI  - The efficacy and safety of complement C5a inhibitors for patients with severe 
      COVID-19: a systematic review and meta-analysis.
PG  - 77-86
LID - 10.1080/14787210.2022.2150165 [doi]
AB  - BACKGROUND: The clinical efficacy and safety of complement C5a inhibitors for 
      patients with severe COVID-19 remains unclear. METHODS: The PubMed, Embase, 
      Cochrane Library, and ClinicalTrials.gov databases were searched from their 
      inception to 27 September 2022. Only studies that assessed the usefulness of C5a 
      inhibitors for the treatment of patients with severe COVID-19 patients were 
      included. The primary outcome was the risk of 28-day mortality. RESULTS: Six 
      studies, including four randomized controlled trials (RCTs) and two non-RCTs, 
      were included. The study group receiving C5a inhibitors had a significantly lower 
      risk of mortality compared with the control group (23.6% [70/297] vs 39.2% 
      [136/347]; odds ratio [OR], 0.53; 95% confidence interval [CI]: 0.37-0.76; 
      P< 0.001), and no heterogeneity was detected (I(2) = 0%; P= 0.58). Compared with 
      control group, the study group was associated with a similar risk of serious 
      adverse events (AEs) (OR, 0.84; 95% CI: 0.57-1.23; P0 = 0.37), infection (OR, 
      1.46; 95% CI: 0.77-2.79; P= 0.25) and acute kidney injury (OR, 0.89; 95% CI: 
      0.54-1.46; P= 0.64). CONCLUSION: C5a inhibitors could help reduce the risk of 
      mortality in patients with severe COVID-19 infection while being as safe as 
      placebos. These findings support the promising role of C5a inhibitors in the 
      treatment of severe COVID-19.
FAU - Tsai, Chi-Lun
AU  - Tsai CL
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AUID- ORCID: 0000-0002-6334-2388
AD  - Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical 
      Center, Tainan, Taiwan.
AD  - School of Medicine, College of Medicine, National Sun Yat-sen University, 
      Kaohsiung, Taiwan.
FAU - Chen, Ching-Yi
AU  - Chen CY
AUID- ORCID: 0000-0002-3320-1680
AD  - Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, 
      Kaohsiung City, Taiwan.
AD  - School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
FAU - Lee, Ho-Sheng
AU  - Lee HS
AUID- ORCID: 0000-0001-5839-8670
AD  - Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, 
      Kaohsiung City, Taiwan.
AD  - School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221129
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
RN  - 80295-54-1 (Complement C5a)
SB  - IM
MH  - Humans
MH  - *COVID-19
MH  - Treatment Outcome
MH  - Complement C5a
OTO - NOTNLM
OT  - C5a
OT  - COVID-19
OT  - SARS-CoV-2
OT  - complement
OT  - mortality
EDAT- 2022/11/19 06:00
MHDA- 2023/01/17 06:00
CRDT- 2022/11/18 15:52
PHST- 2022/11/19 06:00 [pubmed]
PHST- 2023/01/17 06:00 [medline]
PHST- 2022/11/18 15:52 [entrez]
AID - 10.1080/14787210.2022.2150165 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2023 Jan;21(1):77-86. doi: 
      10.1080/14787210.2022.2150165. Epub 2022 Nov 29.